Effectiveness and safety of immunization with live-attenuated and inactivated vaccines for pediatric liver transplantation recipients

被引:55
|
作者
Kawano, Yoshihiko [1 ]
Suzuki, Michio [1 ]
Kawada, Jun-ichi [1 ]
Kimura, Hiroshi [2 ]
Kamei, Hideya [3 ]
Ohnishi, Yasuharu [3 ]
Ono, Yasuyuki [4 ]
Uchida, Hiroo [4 ]
Ogura, Yasuhiro [3 ]
Ito, Yoshinori [1 ]
机构
[1] Nagoya Univ, Grad Sch Med, Dept Pediat, Showa Ku, Nagoya, Aichi 4668550, Japan
[2] Nagoya Univ, Grad Sch Med, Dept Virol, Showa Ku, Nagoya, Aichi 4668550, Japan
[3] Nagoya Univ, Grad Sch Med, Dept Transplantat Surg, Showa Ku, Nagoya, Aichi 4668550, Japan
[4] Nagoya Univ, Grad Sch Med, Dept Pediat Surg, Showa Ku, Nagoya, Aichi 4668550, Japan
关键词
Immunization; Live-attenuated vaccine; Inactivated vaccine; Children; Liver transplantation; VARICELLA INFECTION; HUMORAL IMMUNOGENICITY; VIRUS VACCINE; ZOSTER; MEASLES;
D O I
10.1016/j.vaccine.2015.01.075
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Liver transplantation recipients are at high risk for severe complications due to infections because of being treated with immunosuppressive drugs that affect the immune system. Vaccination for liver transplantation candidates is generally recommended before surgery, but the opportunities for vaccination prior to transplantation in pediatric candidates are often limited by severe disease conditions. Methods: The participants in this study comprised 39 pediatric recipients of living donor liver transplantation performed between 2005 and 2013. Criteria for administering live-attenuated (measles, rubella, mumps, and varicella) and inactivated (hepatitis B, pertussis, and Japanese encephalitis) vaccines were as follows; (1) >1 year after transplantation; (2) no use of systemic steroids to treat acute rejection within the last 6 months; (3) serum trough concentration of tacrolimus <5 ng/mL; (4) no severe immunosuppression according to blood examinations; and (5) provision of written informed consent. Median age at transplantation was 17 months, and median period from transplantation to the beginning of immunization was 18 months. Results: Seroprotection rates for measles, rubella, mumps, varicella, hepatitis B, pertussis, and Japanese encephalitis after post-transplant immunization were 44% (11/25), 70% (19/27), 48% (12/25), 32% (6/19), 83% (19/23), 87% (13/15), and 88% (7/8), respectively. Seroprotection rates for measles, rubella, mumps, and varicella after second vaccination for recipients with primary vaccine failure after first vaccination were 100% (8/8), 50% (1/2), 71% (5/7), and 50% (5/10), respectively. While four recipients contracted mumps and eight contracted varicella before immunization, one recipient developed varicella after immunization. No serious systemic adverse events were observed in vaccinated recipients. Conclusions: Seroprotection rates for measles, mumps, and varicella appeared low in children after the first post-transplantation vaccination. Immunizations with four live-attenuated and three inactivated vaccines were safe and effective for pediatric liver transplantation recipients who were not severely immunosuppressed. (C) 2015 Published by Elsevier Ltd.
引用
收藏
页码:1440 / 1445
页数:6
相关论文
共 50 条
  • [1] Safety and immunogenicity of Russian live-attenuated and US inactivated trivalent influenza vaccines in the elderly
    Rudenko, L
    Arden, N
    Grigorieva, E
    Naychin, A
    Rekstin, A
    Katz, J
    Klimov, A
    Donina, S
    Desheva, J
    Cox, N
    Ghendon, Y
    OPTIONS FOR THE CONTROL OF INFLUENZA III, 1996, 1123 : 572 - 578
  • [2] Live-attenuated vaccination for measles, mumps, and rubella in pediatric liver transplantation
    Keutler, Anne
    Lainka, Elke
    Posovszky, Carsten
    PEDIATRIC TRANSPLANTATION, 2024, 28 (01)
  • [3] Safety of immunization during pregnancy: A review of the evidence of selected inactivated and live attenuated vaccines
    Keller-Stanislawski, Brigitte
    Englund, Janet A.
    Kang, Gagandeep
    Mangtani, Punam
    Neuzil, Kathleen
    Nohynek, Hanna
    Pless, Robert
    Lambach, Philipp
    Zuber, Patrick
    VACCINE, 2014, 32 (52) : 7057 - 7064
  • [4] Live-Attenuated Vaccines in Pediatric Solid Organ Transplant
    Hartley, Christopher
    Thomas, Tina
    Smith, Sara Kathryn
    Karnsakul, Wikrom
    VACCINES, 2024, 12 (04)
  • [5] An overview on inactivated and live-attenuated SARS-CoV-2 vaccines
    Khoshnood, Saeed
    Arshadi, Maniya
    Akrami, Sousan
    Koupaei, Maryam
    Ghahramanpour, Hossein
    Shariati, Aref
    Sadeghifard, Nourkhoda
    Heidary, Mohsen
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2022, 36 (05)
  • [6] Efficacy and synergy of live-attenuated and inactivated influenza vaccines in young chickens
    Jang, Hyesun
    Elaish, Mohamed
    Mahesh, K. C.
    Abundo, Michael C.
    Ghorbani, Amir
    Ngunjiri, John M.
    Lee, Chang-Won
    PLOS ONE, 2018, 13 (04):
  • [7] Live-attenuated Shigella vaccines
    Venkatesan, Malabi M.
    Ranallo, Ryan T.
    EXPERT REVIEW OF VACCINES, 2006, 5 (05) : 669 - 686
  • [8] Combined use of live-attenuated and inactivated influenza vaccines to enhance heterosubtypic protection
    Yan, Li-Meng
    Li, Olive T. W.
    Poh, Chek M.
    Perera, Ranawaka A. P. M.
    Valkenburg, Sophie A.
    Peiris, Malik
    Poon, Leo L. M.
    VIROLOGY, 2018, 525 : 73 - 82
  • [9] ANTIBODY RESPONSE TO IMMUNIZATION WITH LIVE-ATTENUATED VACCINES IN ADULT SURVIVORS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
    Tsuji, M.
    Asano-Mori, Y.
    Narita, M.
    Tsuchihashi, R.
    Ota, H.
    Nishida, A.
    Ishiwata, K.
    Takagi, S.
    Yamamoto, H.
    Yamamoto, G.
    Uchida, N.
    Izutsu, K.
    Wake, A.
    Yoneyama, A.
    Taniguchi, S.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S328 - S328
  • [10] COMPARATIVE-EVALUATION OF IMMUNIZATION WITH LIVE ATTENUATED AND INACTIVATED POLIOVIRUS VACCINES
    OGRA, PL
    COMBINED VACCINES AND SIMULTANEOUS ADMINISTRATION: CURRENT ISSUES AND PERSPECTIVES, 1995, 754 : 97 - 107